Payment overview · 2025
General Payments
$256.42
16 reported records · 11 companies
Healthcare provider profile · identity verified
Christopher Adiletta, MD
Allopathic & Osteopathic Physicians|Family Medicine · EAST SYRACUSE, NY · NPI 1629459664
Verified facts
What the public records show
CMS Open Payments records show Christopher Adiletta, MD received $256.42 in general payments during 2025 across 16 reported records.
Axsome Therapeutics, Inc. accounted for 17.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Rexulti, Synthroid, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Wegovy by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $44.31 | 17.3% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $40.32 | 15.7% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $34.69 | 13.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.24 | 9.1% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $21.50 | 8.4% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $20.14 | 7.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.12 | 5.9% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $14.99 | 5.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.73 | 5.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.91 | 5.4% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $13.47 | 5.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $256.42 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $44.31 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN Normalized: watchman |
Device | Boston Scientific Corporation | $34.69 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $26.26 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $23.24 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $21.50 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $20.14 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $15.12 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $14.99 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.73 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $14.06 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.06 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.91 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $13.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 61 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 42 | exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
42 | 11 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
61 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
85 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 388 | 118 |
| Amlodipine Besylate | Amlodipine Besylate | 266 | 88 |
| Levothyroxine Sodium | Levothyroxine Sodium | 247 | 63 |
| Omeprazole | Omeprazole | 211 | 70 |
| Lisinopril | Lisinopril | 201 | 62 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 180 | 59 |
| Sertraline Hcl | Sertraline Hcl | 151 | 41 |
| Metformin Hcl Er | Metformin Hcl | 144 | 44 |
| Gabapentin | Gabapentin | 137 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 136 | 34 |
| Losartan Potassium | Losartan Potassium | 130 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 127 | 42 |
| Alprazolam | Alprazolam | 118 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 117 | 39 |
| Bupropion Xl | Bupropion Hcl | 114 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 113 | 27 |
| Prednisone | Prednisone | 107 | 78 |
| Mounjaro | Tirzepatide | 102 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 100 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 92 | 48 |
| Tizanidine Hcl | Tizanidine Hcl | 89 | 49 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 89 | 22 |
| Irbesartan | Irbesartan | 86 | 28 |
| Ozempic | Semaglutide | 85 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 83 | 72 |
| Trazodone Hcl | Trazodone Hcl | 80 | 22 |
| Famotidine | Famotidine | 79 | 22 |
| Azithromycin | Azithromycin | 78 | 63 |
| Simvastatin | Simvastatin | 78 | 28 |
| Montelukast Sodium | Montelukast Sodium | 77 | 21 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 76 | 22 |
| Furosemide | Furosemide | 75 | 26 |
| Tramadol Hcl | Tramadol Hcl | 69 | 28 |
| Meloxicam | Meloxicam | 68 | 39 |
| Doxycycline Hyclate | Doxycycline Hyclate | 64 | 52 |
| Jardiance | Empagliflozin | 61 | 22 |
| Alendronate Sodium | Alendronate Sodium | 60 | 20 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 60 | 45 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 58 | 14 |
| Celecoxib | Celecoxib | 56 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 56 | 20 |
| Ezetimibe | Ezetimibe | 55 | 19 |
| Farxiga | Dapagliflozin Propanediol | 54 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 52 | 16 |
| Eliquis | Apixaban | 51 | 14 |
| Allopurinol | Allopurinol | 48 | 15 |
| Trulicity | Dulaglutide | 48 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 45 | 12 |
| Methylprednisolone | Methylprednisolone | 44 | 44 |
| Fluticasone Propionate | Fluticasone Propionate | 42 | 24 |
| Synthroid | Levothyroxine Sodium | 42 | 11 |
| Cephalexin | Cephalexin | 41 | 27 |
| Clonazepam | Clonazepam | 41 | suppressed |
| Spironolactone | Spironolactone | 41 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 40 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | 12 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 37 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 36 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 36 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 35 | suppressed |
| Chlorthalidone | Chlorthalidone | 34 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | 12 |
| Metformin Hcl | Metformin Hcl | 33 | suppressed |
| Potassium Chloride | Potassium Chloride | 33 | 17 |
| Pregabalin | Pregabalin | 32 | suppressed |
| Xarelto | Rivaroxaban | 32 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 31 | suppressed |
| Carvedilol | Carvedilol | 30 | suppressed |
| Repatha Sureclick | Evolocumab | 30 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Mupirocin | Mupirocin | 25 | 19 |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Ramipril | Ramipril | 25 | suppressed |
| Naproxen | Naproxen | 24 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 23 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 18 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 22 | 12 |
| Donepezil Hcl | Donepezil Hcl | 22 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | 19 |
| Levofloxacin | Levofloxacin | 21 | 20 |
| Torsemide | Torsemide | 21 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 20 | suppressed |
| Clotrimazole | Clotrimazole | 20 | 16 |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 20 |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 19 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | suppressed |
| Metronidazole | Metronidazole | 18 | 16 |
| Ofloxacin | Ofloxacin | 18 | 16 |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 17 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | 13 |
| Rybelsus | Semaglutide | 17 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 17 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 17 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 15 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Baqsimi | Glucagon | 14 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 14 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Praluent Pen | Alirocumab | 11 | suppressed |
| Rexulti | Brexpiprazole | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Wegovy | Semaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $256.42 · 16 records | Axsome Therapeutics, Inc. | Auvelity, CAPLYTA, Cologuard Collection Kit, FREESTYLE LIBRE 3, INSPIRE, JARDIANCE, QULIPTA, REXULTI, SYNTHROID, UBRELVY, VOQUEZNA, WATCHMAN, Wegovy | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error